Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m2/day on days 1-5 of a 28 day cycle. No objective evidence of anti-myeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

activity toxicity
4
toxicity low
4
low dose
4
dose clofarabine
4
clofarabine relapsed
4
relapsed refractory
4
refractory myeloma
4
myeloma patients
4
patients refractory
4
refractory multiple
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!